Latest From Biocon Ltd.
Eisai’s lenvatinib is endorsed by an expert panel in India in combination with everolimus, for which multiple generic brands are available in addition to Novartis’ Afinitor. The Swiss multinational isn’t allying with Eisai in India at least for now.
New markets are opening up for Indian firms and China appears to be the flavor of the season, but gaining a strong foothold there is not expected to be even "half as easy" as in the US.
Aurobindo has received further Form 483s from the FDA, while Biocon has received an EIR for its Bengaluru facility. The FDA has also successfully concluded inspections for Indoco and Lupin, while ANI, Aptar and MicroSphere have made strategic moves.
Mylan is preparing to launch a trastuzumab biosimilar in the US, while progress of developing bevacizumab and aflibercept biosimilars continues. Insulin aspart and glargine are also in Mylan’s pipeline.
- Large Molecule
- Medical Devices
- Therapeutic Areas
- Parent & Subsidiaries
- Biocon Ltd.
- Senior Management
Arun Chandavarkar, PhD, CEO
Siddharth Mittal, CFO
Ravi Limaye, Pres., Mktg.
Narendra Chirmule, PhD, SVP & Head, R&D
- Contact Info
Phone: (91) 80 2808 2808
20th KM Hosur Rd.
Bangalore , 560 100
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.